Regorafenib Monohydrate

Modify Date: 2025-08-26 18:14:55

Regorafenib Monohydrate Structure
Regorafenib Monohydrate structure
 Common Name Regorafenib Monohydrate
CAS Number 1019206-88-2 Molecular Weight 500.831
Density N/A Boiling Point N/A
Molecular Formula C21H17ClF4N4O4 Melting Point N/A
MSDS N/A Flash Point N/A

 Use of Regorafenib Monohydrate


Regorafenib monohydrate is a multi-target inhibitor for VEGFR1/2/3, PDGFRβ, Kit, RET and Raf-1 with IC50s of 13/4.2/46, 22, 7, 1.5 and 2.5 nM, respectively.

 Names

Name 4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]-3-fluorophenoxy]-N-methylpyridine-2-carboxamide,hydrate
Synonym More Synonyms

 Regorafenib Monohydrate Biological Activity

Description Regorafenib monohydrate is a multi-target inhibitor for VEGFR1/2/3, PDGFRβ, Kit, RET and Raf-1 with IC50s of 13/4.2/46, 22, 7, 1.5 and 2.5 nM, respectively.
Related Catalog
Target

VEGFR1:13 nM (IC50)

VEGFR2:4.2 nM (IC50)

VEGFR3:46 nM (IC50)

PDGFRβ:22 nM (IC50)

Raf-1:2.5 nM (IC50)

Braf:28 nM (IC50)

BRafV600E:19 nM (IC50)

In Vitro Regorafenib potently inhibits VEGFR2 autophosphorylation in NIH-3T3/VEGFR2 cells with an IC50 of 3 nM. In HAoSMCs, regorafenib inhibits PDGFR-β autophosphorylation after stimulation with PDGF-BB, with an IC50 of 90 nM. Regorafenib inhibits the proliferation of VEGF165-stimulated HUVECs, with an IC50 of 3 nM[1]. Regorafenib causes a concentration-dependent decrease in Hep3B cell growth, having an IC50 of 5 μM. Regorafenib subsequently increases the levels of phospho-c-Jun, a JNK target, but not total c-Jun in Hep3B cells[3].
In Vivo Regorafenib effectively inhibits growth of the Colo-205 xenografts in the dose range of 10-100 mg/kg reaching a TGI of 75% at day 14 at the 10 mg/kg dose. In the MDA-MB-231 model, regorafenib is highly efficacious at a dose as low as 3 mg/kg, resulting in a significant TGI of 81%, which increases to 93% at doses of 10 and 30 mg/kg, where tumor stasis is reached[1].
Kinase Assay Initial in vitro kinase inhibition profiling is performed at Millipore Corporation at a fixed 1 μM compound concentration under Millipore standard conditions [10 μM adenosine-5′-triphosphate (ATP) concentration]. Inhibitory concentration of 50% (IC50) values are determined from selected responding kinases,e.g., VEGFR1 and RET. TIE2 kinase inhibition is measured with a homogeneous time-resolved fluorescence (HTRF) assay using a recombinant fusion protein of glutathione-S-transferase, the intracellular domain of TIE2 and the peptide biotin-Ahx-EPKDDAYPLYSDFG as substrate[1].
Cell Assay For proliferation assays, GIST 882 and TT cells are grown in RPMI medium containing L-glutamine, and MDA-MB-231, HepG2 and A375 cells in DMEM always containing 10% hiFBS. Cells are trypsinized, plated at 5×104 cells/well in 96-well plates in complete media containing 10% FBS and grown overnight at 37°C. The next day, vehicle or Regorafenib serially diluted in complete growth media to between 10 μM and 5 nM final concentrations, and 0.2% DMSO, is added and incubation is continued for 96 hr. Cell proliferation is quantified using CellTitre-GloTM[1].
Animal Admin Mice[1] Female athymic NCr nu/nu mice are subcutaneously inoculated with 5×106 Colo-205 or MDA-MB-231 cells or implanted with 1 mm3 786-O tumor fragments. When tumors reach a volume of 100 mm3, Regorafenib or vehicle control is administered orally qd×21 in the 786-O model, and qd×9 in the Colo-205 and MDA-MB-231 models, respectively, at doses of 100, 30, 10, and 3 mg/kg. Paclitaxel is administered intravenously at 10 mg/kg in ethanol/Cremophor EL®/saline (12.5%/12.5%/75%) every 2 days×5. Tumor size (volume) is estimated twice weekly (l×w2)/2, and the percentage of tumor growth inhibition (TGI) is obtained from terminal tumor weights (1-T/C×100). Mice are weighed every other day starting from the first day of treatment. The general health status of the mice is monitored daily.
References

[1]. Wilhelm SM, et al. Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity. Int J Cancer, 2011, 129(1), 245-255.

[2]. Heng DY, et al. Targeted therapy for metastatic renal cell carcinoma: current treatment and future directions. Ther Adv Med Oncol, 2010, 2(1), 39-49.

[3]. Carr BI, et al. Fluoro-Sorafenib (Regorafenib) effects on hepatoma cells: growth inhibition, quiescence, and recovery. J Cell Physiol, 2013, 228(2), 292-297.

 Chemical & Physical Properties

Molecular Formula C21H17ClF4N4O4
Molecular Weight 500.831
Exact Mass 500.087433
PSA 105.07000
LogP 6.10200
Storage condition -20℃

 Synonyms

2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]-3-fluorophenoxy]-N-methyl-, hydrate (1:1)
MGN125FS9D
regorafenib monohydrate
4-[4-({[4-Chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methyl-2-pyridinecarboxamide hydrate (1:1)
4-[4-({[4-chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide monohydrate
Regorafenib (monohydrate)
Regorafenib hydrate [JAN]
bay 73-4506 monohydrate
UNII-MGN125FS9D
4-[4-({[4-chloro-3-(trifluoromethyl) phenyl] carbamoyl} amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide monohydrate
Stivarga
regorafenib hydrate
4-[4-({[4-chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-pyridine-2-carboxylic acid methylamide monohydrate
Stivarga (TN)
The content on this webpage is sourced from various professional data sources. If you have any questions or concerns regarding the content, please feel free to contact service1@chemsrc.com.
Top Suppliers:I want be here

Get all suppliers and price by the below link:

Regorafenib Monohydrate suppliers

Price: $86/10mM*1mLinDMSO

Reference only. check more Regorafenib Monohydrate price

Related Compounds: More...
Regorafenib-13C-d3
2126178-55-8
Regorafenib D3
1255386-16-3
Regorafenib (BAY 73-4506)
755037-03-7
Regorafenib N-Oxide(M2)
835621-11-9
Regorafenib
835621-08-4
Regorafenib Impurity 18
1379324-09-0
Regorafenib (Hydrochloride)
835621-07-3
BAICALEIN, MONOHYDRATE
352000-07-8
BERGENIN MONOHYDRATE
108032-11-7
(4-(((4-Methoxyphenyl)thio)methyl)piperidin-1-yl)(2-(methylthio)phenyl)methanone
1421484-01-6
2-(2-Chlorophenyl)-1-(4-(((4-methoxyphenyl)thio)methyl)piperidin-1-yl)ethanone
1421451-05-9
N-(3-hydroxy-3-phenylpropyl)adamantane-1-carboxamide
1421452-30-3
N-(3-hydroxy-3-phenylpropyl)-3,5-dimethoxybenzamide
1396747-08-2
N-(3-hydroxy-3-phenylpropyl)-2-(trifluoromethyl)benzamide
1396876-42-8
3,4-dichloro-N-(3-hydroxy-3-phenylpropyl)benzamide
1396847-84-9
N-(3-hydroxy-3-phenylpropyl)-7-methoxybenzofuran-2-carboxamide
1396747-48-0
(4-(((4-Methoxyphenyl)thio)methyl)piperidin-1-yl)(1-(methylsulfonyl)piperidin-4-yl)methanone
1421522-94-2
N-(3-hydroxy-3-phenylpropyl)-[1,1'-biphenyl]-4-carboxamide
1396805-50-7
N-(3-hydroxy-3-phenylpropyl)-4-phenyltetrahydro-2H-pyran-4-carboxamide
1396790-47-8
Chemsrc provides Regorafenib Monohydrate(CAS#:1019206-88-2) MSDS, density, melting point, boiling point, structure, formula, molecular weight etc. Articles of Regorafenib Monohydrate are included as well.>> amp version: Regorafenib Monohydrate

Home | MSDS/SDS Database Search | Journals | Product Classification | Biologically Active Compounds | Selling Leads | About Us | Disclaimer

Copyright © 2024 ChemSrc All Rights Reserved